LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung Y. L. Wu, C. Zhou, C. P. Hu, J. Feng, S. Lu, Y. Huang, W. Li, M. Hou, J. H. Shi, K. Y. Lee, D. Massey, Y. Shi, J. J. Chen, V. Zazulina, S. L. Geater (Guangzhou, Shanghai, Changsha, Nanjing, Kunming, Changchun, Chengdu, Linyi, China; Seoul, Republic Of Korea; Bracknell, United Kingdom; Songkhla, Thailand)
Source: Annual Congress 2013 –Advances in the therapy of lung cancer
Session: Advances in the therapy of lung cancer Session type: Oral PresentationNumber: 371
Disease area: Thoracic oncologyRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. L. Wu, C. Zhou, C. P. Hu, J. Feng, S. Lu, Y. Huang, W. Li, M. Hou, J. H. Shi, K. Y. Lee, D. Massey, Y. Shi, J. J. Chen, V. Zazulina, S. L. Geater (Guangzhou, Shanghai, Changsha, Nanjing, Kunming, Changchun, Chengdu, Linyi, China; Seoul, Republic Of Korea; Bracknell, United Kingdom; Songkhla, Thailand). LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. Eur Respir J 2013; 42: Suppl. 57, 371
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: LUX-Lung 7 Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016
Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014
Multicenter phase II trial of carboplatin (Cb) and gemcitabine (G) followed by concurrent chemoradiation (CRT) in patients with unresectable stage III non-small-cell-lung cancer (NSCLC): Cher@Nos trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008
Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non small cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003
Randomized phase II study of adjuvant cisplatin/docetaxel (Cis-Doc) or cisplatin/vinorelbine (Cis-VRB) in patients (pts) with resected stage IB-II NSCLC: interim analysis Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Safety analysis of anti-VEGF therapy bevacizumab (Bv) in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC) in MO19390 (SAiL) trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008
A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
A randomised phase III comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002
Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005
Gemcitabine plus vinorelbine (GV) or paclitaxel (GT) versus gemcitabine (G) or paclitaxel (T) alone in elderly or unfit nonsmall cell lung cancer (NSCLC) patients. SICOG 9909 phase III trial Source: Eur Respir J 2003; 22: Suppl. 45, 527s Year: 2003
A multicenter phase II study of carboplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC) in elderly patients (GFPC 9902) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003
A three-arm phase III randomised trial assessing, in patients with extensive-disease (ED) small-cell lung cancer (SCLC), accelerated chemotherapy with the support of haematological growth factor or of oral antibiotics Source: Eur Respir J 2001; 18: Suppl. 33, 319s Year: 2001
LATE-BREAKING ABSTRACT: Triplet chemotherapy (paclitaxel/gemcitabine/cisplatin) is more active in advanced squamous cell subtype (SCC) non-small cell lung cancer (NSCLC) than doublet treatment (vinorelbine/cisplatin): A randomized phase III trial in 443 NSCLC patients Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012
Carboplatin (C), paclitaxel (T) and etoposide (E) and early concurrent thoracic radiotherapy (TRT) for patients with limited disease small cell lung cancer (LD-SCLC): a Dutch multicentre phase 2 study Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002
LATE-BREAKING ABSTRACT: A mRNA signature predicts outcome of patients (pts) with advanced non small cell lung cancer (NSCLC) treated with cisplatin (C) and vinorelbine (V): A ELCWP prospective study Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP) Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006